期刊
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
卷 1870, 期 2, 页码 239-246出版社
ELSEVIER
DOI: 10.1016/j.bbcan.2018.06.004
关键词
Preclinical models; Patient-derived xenografts (PDX); Organoids
资金
- FEDER funds
- Carlos III Health Institute, Spain [CD15/00153, MV16/00050]
- Generalitat Valenciana, Spain [BEST/2016/035]
- Fondo de Investigaciones Sanitarias (Carlos III Health Institute, Spain) from the Spanish Government [PI15/02180]
- CIBERONC [CB16/12/00481-CB16/12/00473]
- European Community's Seventh Framework Programme [602901]
- H2020 grant [635342-2]
- IMI [115749]
- AIRC IG [16788]
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 e 2014 Ministero della Salute
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS Innovation 5 per mille 2012 MIUR
- AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille [9970]
- AIRC Special Program 5 per mille Metastases, 'Insights into the evolving heterogeneity of metastatic colorectal cancer: from mechanisms to therapies' [21091]
Precision medicine approaches have revolutionized oncology. Personalized treatments require not only identification of the driving molecular alterations, but also development of targeted therapies and diagnostic tests to identify the appropriate patient populations for clinical trials and subsequent therapeutic implementation. Preclinical in vitro and. in vivo models are widely used to predict efficacy of newly developed treatments. Here we discuss whether, and to what extent, preclinical models including cell lines, organoids and tumorgrafts recapitulate key features of human tumors. The potential of preclinical models to anticipate treatment efficacy and clinical benefit is also presented, using examples in different tumor types.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据